FindTrial
Sign In

Study of antifungal drug susceptibility in fungal infections of the skin

A study of in-vitro drug susceptibilty patterns of dermatophytes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2014/11/005219
Enrollment
80
Registered
2014-11-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Superficial dermatophyte infections of the skin

Interventions

None listed

Sponsors

IADVL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients clinically diagnosed to be suffering from superficial dermatophytosis

Exclusion criteria

Exclusion criteria: 1. Clinical evidence of superadded bacterial infection 2. Patients not consenting to provide a sample

Design outcomes

Primary

MeasureTime frame
Identifying the causative agents responsible for dermatophyte infections in Mumbai, India 2. To determine the minimum inhibitory concentration values( MIC 50 & MIC 80 ) OF THE FOLLOWING DRUGS : Terbinafine, Griseofulvin, Fluconazole, Itraconazole, Ketoconazole, Clotrimazole and Sertaconazole against these dermatophytesTimepoint: One Year—

Secondary

MeasureTime frame
To select the best antifungal drug for a patient of Dermatophytosis. thereby reducing the disease morbidityTimepoint: 1year—

Countries

India

Contacts

Public ContactDr Jimish Bagadia

Department of Dermatology, K.J.Somaiya Medical College

spoojary2004@gmail.com9820601511

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026